CliffBio
small molecule

OXTELLAR XR

OXCARBAZEPINE

Loss of exclusivityApril 2027latest FDA-listed patent expiry
CompanySupernus Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameOXTELLAR XR
Active ingredientOXCARBAZEPINE
Strength600MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2012
Marketing statusRX

Listed patents

PatentExpiresType
7910131April 2027use U-2041
9119791April 2027use U-2041
10220042April 2027use U-2501
9370525April 2027product
9855278April 2027product
11166960April 2027product
7722898April 2027product
8821930April 2027product
9351975April 2027product
8617600April 2027product
11896599April 2027product

More from Supernus Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OXTELLAR XR patent cliff — loss of exclusivity April 2027 | CliffBio